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Kallikreins 
Kallikrein (EC 3.4.21.8) specifies those serine proteinases which liberate kinins 
from kininogens by limited proteolysis and have no or only little proteolytic 
activity on other proteins (for review, see refs. 2,3,21). Unfortunately, this defini-
tion fits two totally different groups of proteinases: the glandular, tissue or organ 
kallikreins on the one hand, and the plasma or serum kallikrein on the other. 
The two types differ (a) in physicochemical properties; (b) in the type of kinin 
they release (plasma kallikreins: bradykinin; glandular kallikreins: kallidin = lysyl-
bradykinin); (c) in immunochemical properties (no cross-reactivity of the one 
type with antiserum directed against the other type has ever been observed); 
and (d) in susceptibility to inhibition by natural proteinase inhibitors. 
The plasma kallikrein plays an important role in the coagulation/fibrinolysis 
system (21). The physiological function of the glandular kallikreins is still to 
a large degree a matter of speculation. Glandular kallikreins are found in pan-
creas, salivary and sweat glands, intestines, kidney, and urine. 
PROPERTIES OF PIG G L A N D U L A R K A L L I K R E I N S 
The biochemically best characterized glandular kallikreins are the urinary, 
submandibular, and especially pancreatic kallikrein of the pig (12). These three 
glandular kallikreins have been isolated and highly purified. On isoelectric focus-
ing the pure enzymes show numerous multiple forms with slightly different 
isoelectric points close to pH 4. Another type of heterogeneity is revealed by 
SDS-polyacrylamide gel electrophoresis of reduced submandibular and urinary 
kallikrein. With both enzymes two protein bands are obtained. In analogy 
to the two forms of pancreatic kallikrein originally described by Habermann 
(13) the faster migrating component is called "A-form" and the slower one 
"B-form." For pancreatic kallikrein it was shown that the two forms differ in 
their carbohydrate content: the A-form contains about 5.6%, thé B-form about 
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11.5% carbohydrate. It is assumed that also the differences of the A - and 
B-forms of submandibular and urinary kallikrein are a reflection of different carbo-
hydrate contents (Table 1). 
Pig pancreatic kallikrein B, isolated from autolyzed pancreas, consists of two 
polypeptide chains connected by disulfide bridges. This form was denoted 
/?-kallikrein (Table 1). By comparing the amino acid compositions of the two-
T A B L E 1. Molecular forms of pig glandular kallikreins 
D e s i g n a t i o n De f in i t i on 
Ka l l i k re in A A a n d B d i f fe r in the i r 
Ka l l i k re in B c a r b o h y d r a t e c o n t e n t 
a -Ka l l i k re in S i n g l e p o l y p e p t i d e c h a i n 
/3-Kall ikrein T w o p o l y p e p t i d e c h a i n s l i n k e d b y 
d i su l f i de b r i d g e s 
chain pancreatic /3-kallikrein and of the single-chain submandibular and urinary 
a-kallikreins, a difference of three amino acids is revealed: Obviously, the pan-
creatic /3-kallikrein has lost, by limited proteolytic cleavage during tissue autoly-
sis, a tripeptide which originally formed the linkage between the two chains 
(4,28). 
The apparent molecular weights of the pure kallikrein preparations were deter-
mined by SDS-polyacrylamide gel electrophoresis and ultracentrifugation (12) 
(Table 2). For the neuraminidase-treated pancreatic ß-kallikrein B, a somewhat 
lower molecular weight was found than for urinary and submandibular kallikrein, 
probably reflecting differences in the carbohydrate moieties of the three enzymes 
(12). 
The amino acid sequences of the two chains of pancreatic /3-kallikrein have 
been elucidated by Fiedler et al. (4) and Tschesche et al. (27). The comparison 
T A B L E 2. Molecular weights of pig glandular kallikreins 
Ka l l i k re in ß - P a n c r e a t i c a S u b m a n d i b u l a r Ur ina ry 
S D S - p o l y a c r y l a m i d e ge l e l e c t r o p h o r e s i s 
Mr a p p 35,900 ( f o r m A ) 36,100 ( f o r m A ) 
Mr a p p 34,600 b f o r m B 39,600 ( f o r m B) 39,600 ( f o r m B) 
U I t racent r i f u g a t i o n c 
'r 28,000 ± 1 0 0 0 38,000 ± 1 0 0 0 40,000 ± 1 5 0 0 
° N e u r a m i n i d a s e - t r e a t e d . 
" T o t a l o f t h e m o l e c u l a r w e i g h t s o f t h e t w o c h a i n s o f t h e /3-kall ikrein. 
c T h e r e s u l t s w e r e o b t a i n e d b y h igh s p e e d s e d i m e n t a t i o n e q u i l i b r i u m r u n s a n d b y a c t i v e 
e n z y m e c e n t r i f u g a t i o n (12). 
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T A B L E 3. Relative rates of ester hydrolysis catalyzed by pig glandular kallikreins 
Ka l l i k re in 
S u b s t r a t e ^ - p a n c r e a t i c , B S u b m a n d i b u l a r U r i na ry 
A c - P h e - A r g - O M e 5 7 8 2 5 7 2 6 6 
B z - A r g - O M e 1 1 2 8 7 . 3 9 5 . 5 
B z - A r g - O E t 9 5 . 5 6 9 . 8 7 3 . 6 
T o s - A r g - O E t 2 .73 2 . 5 7 2 .99 
B z - L y s - O M e 4 . 2 3 0 .86 1.19 
A c - T y r - O E t 0 .25 0 .21 0 .19 
B z - M e t - O M e 0 .18 0 .12 0 . 1 2 
T h e h y d r o l y s i s r a t e s w e r e m e a s u r e d o n t h e au to t i t r a to r a n d r e l a t e d t o r a t e = 
1 0 0 fo r e a c h ka l l i k re in a t 10 m M B z - A r g - O E t . C o n d i t i o n s : 1 nriM s u b s t r a t e , 0.1 m 
N a C I , 0.1 m M e t h y l e n e d i a m i n e t e t r a a c e t i c a c i d , p H 8.0, a t 2 5 ° C . 
D a t a f r o m Fr i tz e t a l . , réf. 12 . 
with the amino acid sequence of porcine trypsin revealed a degree of homology 
of 51%. 
Evidence for identical amino acid sequences of the three pig glandular kalli-
kreins was obtained from studies of the amino terminal sequences of urinary 
and submandibular kallikreins. The sequences of the first 10 amino acids of 
submandibular and of the first 28 amino acids of urinary kallikrein are identical 
with the corresponding sequence of pancreatic kallikrein (27). 
The comparison of hydrolysis rates of synthetic substrates (Table 3) as well 
as the accessibility to inhibition by natural and synthetic inhibitors (1,12) (Table 
4) measured for the three kallikreins indicates a high degree of similarity of 
the single-chain submandibular and urinary a-kallikreins, whereas the two-chain 
pancreatic /?-kallikrein differs distinctly. These differences observed for the pan-
creatic kallikrein are in all probability due to the intrachain split. For single-
chain pancreatic kallikrein, presently under investigation by Dr. Fiedler in our 
department, such differences in enzymatic properties should not exist. 
T A B L E 4 . Apparent dissociation constants Ki (nmoles/l) of pig glandular kallikrein-
inhibitor complexes 
Ka l l i k re in 
Inh ib i to r f r o m : P a n c r e a t i c S u b m a n d i b u l a r U r i na ry 
B o v i n e l u n g (TKI ) 0 .8 0 .9 1.0 
S e a a n e m o n e (SAI -5- I I ) 0 .8 0 .6 0 .8 
S n a k e v e n o m (NNV- I I ) 1.1 1.3 1.3 
S n a k e v e n o m (HHV- I I ) 8 .3 2 1 0 1 0 9 
S n a i l ( H P I K ) 2 7 . 7 2 1 0 2 0 4 
Abbreviations: T K I , a p r o t i n i n ( T r a s y l o l ® ) ; SA I -5 - I I , f r a c t i o n 5-II f r o m Anemonia sul-
cata; N N V - I I , f r a c t i o n II f r o m s n a k e (Naja naja) v e n o m ; H H V - I I , f r a c t i o n II f r o m s n a k e 
(Hemachatus hemachatus) v e n o m ; H P I K , i so inh ib i to r K f r o m Helix pomatia. T h e f i ve 
i n h i b i t o r s a r e s t ruc tu ra l l y h o m o l o g o u s (1 ). 
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The antigenic relationship between the three pig glandular kallikreins was 
first studied by double-diffusion experiments (12). The precipitin lines formed 
during diffusion of the three kallikreins against rabbit antisera to any of the 
three enzymes were completely confluent, indicating immunological identity 
of the three kallikreins. Immunoelectrophoretic studies demonstrated clearly 
different electrophoretic mobilities, but also immunological identity of the three 
kallikreins (12). 
Hence, all evidence accumulated from physicochemical, immunochemical, 
enzyme-kinetic, inhibition, and structural studies indicates a high degree of 
similarity or even identity of the polypeptide chain of the three pig glandular 
kallikreins. Existing differences obviously reflect differences in the carbohydrate 
moieties of these glycoproteins and different stages of limited proteolytic degrada-
tion. 
STUDIES O N T H E BIOLOGICAL R O L E OF G L A N D U L A R 
KALLIKREINS 
Binding of Glandular Kallikreins to Serum Proteins 
The only serum protein so far known to react with glandular kallikrein is 
oti-antitrypsin (11). For a2-macroglobulin, Vathera and Hamberg (28) demon-
strated convincingly that it does not bind urinary and pancreatic kallikrein. 
Recently we began to examine if, in addition to cti-antitrypsin, other kallikrein 
binding proteins are present in human serum. 
In these studies pig pancreatic 125I-kallikrein was incubated with human serum 
at 37°C. After 10 min, 30 min, and 14 hr incubation, approximately 25, 39, 
and 66%, respectively, of the labeled kallikrein was bound to serum proteins, 
as determined by gel filtration of the incubation mixture and subsequent measur-
ing of the radioactivity in the eluted fractions. As these data demonstrate, the 
binding of active kallikrein to plasma protein(s) occurs relatively slowly—at 
least in the pig pancreatic kallikrein and human serum systems—even after 
14 hr the reaction is still incomplete. 
To discriminate between true and unspecific binding, 125I-kallikrein inactivated 
by diisopropylphosphorofluoridate (DFP) was employed. In this case, after 14 
hr incubation 30% of the radioactivity was bound to serum proteins. Obviously, 
in addition to the interaction of kallikrein with inhibitor(s) an unspecific binding 
of glandular kallikrein to serum proteins also takes place, which is not dependent 
on the enzymatic activity. 
Partial identification of the kallikrein binding proteins was achieved by crossed 
immunoelectrophoresis and subsequent staining and autoradiography of the elec-
trophoretograms. ai-Antitrypsin was clearly the prevailing inhibitor of pig pan-
creatic kallikrein. In addition, some other serum proteins are able to bind the 
enzyme: for example, a2-macroglobulin, ai-antichymotrypsin, the Cl-inactiva-
tor, and antithrombin III. From our experiments it is not yet clear to what 
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extent these interactions are specific, because some binding also occurred in 
the control with DFP-inactivated kallikrein; for example, to a2-macroglobulin 
and especially to antithrombin III, yet almost no binding of DFP-inactivated 
kallikrein to oti-antitrypsin was observed. In order to distinguish between specific 
and nonspecific binding to the various serum proteins, more studies will be 
necessary using quantitative identification methods and purified preparations 
of serum proteins. 
RADIOIMMUNOASSAY 
The radioimmunoassay technique is highly suitable for studies on the fate 
and the functions of exogenous and endogenous glandular kallikreins in the 
organism because of the high sensitivity and high specificity of this method. 
At first a radioimmunoassay for pig pancreatic kallikrein was developed (5,8) 
which is highly specific for the pig glandular kallikreins. With the available 
antiserum to pig pancreatic kallikrein, no cross-reactivity was detected for por-
cine trypsin, bovine trypsin, and chymotrypsin, and kallikreins of guinea pig 
submandibular and coagulation glands. In contrast, dose-response curves of 
pig submandibular and urinary kallikrein paralleled the pancreatic kallikrein 
standard curve, again indicating immunochemical identity of the three pig glan-
dular kallikreins (Fig. 1). Remarkably, dose-response curves were also obtained 
for human urinary kallikrein which nearly paralleled the pig pancreatic kallikrein 
standard curve (Fig. 2). The cross-reactivity calculated from the 50% intercept 
was approximately 4%, i.e., the amount of human urinary kallikrein yielding 
Porcine pancreat ic kallikrein [ng] 
F I G . 1 . D o s e - r e s p o n s e c u r v e s o f p i g g l a n d u l a r ka l l i k re ins . Open circles, s u b m a n d i b u l a r ; closed 
circles, p ig p a n c r e a t i c ; squares, u r i na ry ka l l i k re in . 
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PPK [ng] 
F I G . 2 . D e m o n s t r a t i o n of c r o s s - r e a c t i v i t y o f h u m a n ur inary ka l l i k re in ( H U K ) w i t h a n t i s e r u m t o 
p ig p a n c r e a t i c ka l l i k re in (PPK) u n d e r r a d i o i m m u n o a s s a y c o n d i t i o n s . D o s e - r e s p o n s e c u r v e o f 
P P K (closed squares) a n d H U K (open squares). 
a 50% inhibition of binding of pig pancreatic 125I-kallikrein to the antibody is 
25-fold higher for human urinary kallikrein than for pig pancreatic kallikrein. 
Obviously, there is a much closer immunochemical similarity between glandular 
kallikreins of different species than between glandular kallikreins and structurally 
related serine protease like trypsin of the same species. The lower detection 
limit of pig pancreatic kallikrein in the radioimmunoassay is approximately 
20 pg corresponding to a concentration of 200 pg/ml. 
Intestinal Absorption 
During the past few years evidence has accumulated that enteral and parenteral 
administration of pig pancreatic kallikrein can normalize several pathologic dis-
orders: Schill (24) demonstrated in double-blind studies an increase both in 
sperm count and motility in patients with asthenozoospermia and oligozoosper-
mia after intramuscular and oral administration of pig pancreatic kallikrein. 
Wicklmayr and Dietze (29) found an enhancing effect on muscular glucose 
uptake in maturity onset diabetics. Overlack and co-workers (20) showed that 
in a group of patients with essential hypertension and subnormal excretion of 
urinary kallikrein both parameters normalized after oral administration of pig 
pancreatic kallikrein. Since the observed effects were similar both after intramus-
cular injection and after oral administration of stomach-resistant tablets (23), 
not a mediator function of the intestinal tract but access to the blood stream 
seems to be obligatory for the action of the administered kallikrein. 
As a first step towards clarification of what happens between oral intake of 
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kallikrein and the observed effect, we investigated if pig pancreatic kallikrein 
can be absorbed by the intestine using the rat as a model (6,7,9,10). 
Ten milligrams pig pancreatic kallikrein, dissolved in 1 ml 0.9% saline, was 
injected into the lumen of the duodenum of anesthetized rats. Lymph was col-
lected from the thoracic duct and blood samples were drawn from the tail 
vein. A l l samples were measured by radioimmunoassay. Pig pancreatic kallikrein 
was detected in the samples in concentrations of up to 200 ng/ml within 4 hr 
after injection, demonstrating that intestinal absorption had taken place. How-
ever, the absorption kinetics were highly variable within a series of identical 
experiments, with both fasted and unfasted rats. In some experiments no absorp-
tion at all could be observed. 
The two experiments shown in Fig. 3 were selected to demonstrate the high 
variability. The experiments were carried out under identical conditions. The 
highest absorption into lymph that we ever found was 1.5 ppm of the adminis-
tered dose. 
In order to clarify if the radioimmunoassayable material consisted of low 
molecular weight degradation products, samples of lymphatic fluid were sub-
jected to gel filtration and the eluted fractions tested by radioimmunoassay. 
Two peaks of immunochemically active material were found, the smaller one 
E 
200-
— Serum 
— Lymph 
F I G . 3 . K i n e t i c s o f i n tes t ina l a b s o r p t i o n 
o f p i g p a n c r e a t i c ka l l i k re in i n t o s e r u m 
a n d l y m p h of ra t s a f te r i n t r a d u o d e n a l a d -
m i n i s t r a t i o n . 
Time [h ] 
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in the elution position of pig pancreatic kallikrein, the larger one in the position 
of a molecular weight of about 80,000, indicating that most of the intestinally 
absorbed kallikrein was bound to a plasma protein, probably ai-antitrypsin. 
No immunoreactive material at all was found in the region below the molecular 
weight of pig pancreatic kallikrein where degradation products are to be expected. 
In spite of the high variability the experimental results demonstrate that unde-
graded glandular kallikrein can be absorbed by the intestine. The partial binding 
to, presumably, ai-antitrypsin suggests that most of the absorbed kallikrein 
was enzymatically active. Furthermore, the results indicate a significant role 
of the lymphatics in the intestinal absorption of kallikrein in addition to the 
absorption by the mesenteric vein route which was demonstrated earlier by 
Moriwaki and co-workers (18) using a mesenteric perfusion system. The intesti-
nal absorption of undegraded kallikrein is not a singularity, a whole variety 
of other proteins is known to be absorbed as intact molecules, for example, 
insulin, immunoglobulin, chymotrypsin, chymotrypsinogen, trypsin, lipase, and 
albumin (see ref. 15, 26). 
G L A N D U L A R K A L L I K R E I N IN B L O O D 
The radioimmunoassay was further applied to investigate if endogenous glan-
dular kallikrein is present in the blood (6,7,9,10). When samples of pig serum 
or plasma were assayed, concentrations of up to 20 ng/ml were found. Unfortu-
nately, the dose-response curves did not parallel the standard curve; therefore, 
an exact quantitative measurement of glandular kallikrein in blood is not yet 
feasible. Yet the results indicate strongly the presence of a glandular kallikrein-
like antigen in blood. 
In order to further characterize the kallikrein-like antigen gel filtration experi-
ments were performed. Serum and urine samples of the same pig obtained at 
the same time were gel filtrated on Ultragel A C A 44 or Sephacryl S 200 and 
the eluted fractions assayed by radioimmunoassay (Fig. 4). The similar elution 
positions of the radioimmunoassayable material indicate that the molecular 
weight of the kallikrein-like antigen in blood is very close to that of urinary 
kallikrein. 
In this connection it has to be regarded that, in the radioimmunoassay, any 
substance reacting with the labeled antigen in a way that reduces the binding 
to the antibody would simulate the presence of antigen. Especially for the radio-
immunoassay of proteinases in serum where proteinase inhibitors are present 
this type of interference has to be considered. However, ai-antitrypsin, as deter-
mined by a trypsin inhibition assay, was eluted at a position corresponding to 
a higher molecular weight than that of the kallikrein-like antigen. No other 
plasma inhibitor of glandular kallikrein with a molecular weight similar to that 
of glandular kallikrein is known. Therefore, it seems highly unlikely that the 
peak of radioimmunoassayable material detected in the gel filtration eluate of 
the serum sample is caused by such a substance. 
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Gel filtration experiments were also done with human serum. In this case 
the peak of antigenic activity (employing antiserum to human urinary kallikrein 
in the radioimmunoassay) was eluted in the range of 60,000 to 80,000 dalton 
(ai-antitrypsin, for comparison, 54,000 dalton), whereas the elution position 
of the purified human urinary kallikrein corresponded to about 50,000 dalton. 
Therefore, the evidence for the presence of glandular kallikrein in human blood 
is not yet as conclusive as for porcine blood. However, in analogy to our results 
with porcine blood, the results of other groups with the rat (19,22; Rabito et 
al., t h i s volume) and the tendency of human urinary kallikrein to associate 
with hydrophobic substances (R. Geiger et al., u n p u b l i s h e d ) lead us to conclude 
that glandular kallikrein is also present in human blood. Final proof for the 
identity of the kallikrein-like antigen in blood with glandular kallikrein will 
only be possible after its isolation and characterization. 
In addition to all the evidence accumulated so far regarding the occurrence 
of glandular kallikrein in blood of various species, the fact that other pancreatic 
enzymes such as lipase, amylase, chymotrypsin, chymotrypsinogen, trypsin, pan-
creatic elastase, and carboxypeptidase B were found in blood suggests that glan-
dular kallikrein, at least pancreatic kallikrein, should also be present. Two ways 
of access are possible: by release into the local glandular circulation, directly 
or via the lymphatic route, and/or via intestinal absorption. The exact origin 
of the kallikrein-like antigen in blood is not yet known, and also, the question 
of whether the antigen is enzymatically active kallikrein or inactive prekallikrein 
cannot yet be answered. 
R E N A L EXCRETION OF G L A N D U L A R K A L L I K R E I N 
The presence of glandular kallikrein in blood led us to the assumption 
that glomerular filtration might partly be responsible for the occurrence of glan-
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dular kallikrein in urine. Experiments on the renal excretion of pig pancreatic 
kallikrein during intravenous infusion into dogs corroborate this assumption. 
Pig pancreatic kallikrein, 0.5 mg dissolved in 250 ml saline, was infused over 
a 2-hr period into the femoral vein of anesthetized dogs. Blood samples were 
drawn from the femoral artery and urine was collected in 30-min periods from 
the bladder. 
During the infusion a broad maximum of the kallikrein concentration in 
the plasma was reached, being of the same order of magnitude as the concentra-
tion measured by radioimmunoassay in porcine blood (Fig. 5, upper panel). 
The concentration in urine, estimated also by radioimmunoassay, was up to 
fivefold higher than the plasma concentration, thus proving that the pig pan-
creatic kallikrein was indeed excreted by the kidney and did not originate from 
the small amounts of blood by which some urine samples were contaminated. 
The middle part of Fig. 5 shows the clearances determined for inulin and pig 
pancreatic kallikrein for intervals of 30 min. The relative clearance of kallikrein, 
related to the inulin clearance, was approximately 4%, which is in the same 
range as the amylase clearance determined in man (16). The lower panel of 
Fig. 5 shows the amounts of kallikrein excreted during the single urine collection 
periods. The total excreted kallikrein in five experiments was 1 to 3% of the 
administered dose. 
In order to ascertain that not only kallikrein of a different species can be 
excreted, so far one experiment with a pig was carried out. Since the endogenous 
pig urinary kallikrein cannot be distinguished from the exogenous pig pancreatic 
kallikrein by radioimmunoassay, high doses of kallikrein (300-1,000 jxg) were 
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administered and the excretion rate of kallikrein determined. After the adminis-
tration of the high doses the renal excretion rate increased up to 20-fold. The 
most likely explanation is that the increase was due to excretion of the adminis-
tered kallikrein, since an increase of synthesis and secretion of kidney kallikrein 
after administering exogenous glandular kallikrein has never been observed. 
The experiments with both dog and pig demonstrate that glandular kallikrein 
can be transferred from the blood stream to the urine by the kidney, most 
likely by glomular filtration since the kidney was functioning adequately as 
judged by the inulin clearance and the protein excretion (Fig. 5). The results 
reported by Mills et al. (17) do not contradict ours: Mills and co-workers found 
that after intravenous injection of pig pancreatic 1 2 5I-kallikrein into rabbits, 
about 8% of the administered radioactivity was excreted in the urine as kallikrein 
and 32% as low molecular weight degradation products. The authors concluded 
that glomerular filtration would not contribute significantly to the renal excretion 
of kallikrein into the urine. However, calculated from the clearance of pig pan-
creatic kallikrein found in the dog (approximately 2.5 ml/min) and the (prelimi-
nary) concentration of glandular kallikrein in blood (10-20 ng), a daily excretion 
of about 50 jig of glandular kallikrein would result, which is in the range of 
several ten percent of the daily excretion of urinary kallikrein in man. Therefore, 
since kallikrein is present in blood, as indicated by the results described above 
and by the findings of other authors (19,22; Rabito et al., t h i s volume), it has 
to be assumed that it can be transferred into the urine by glomerular filtration. 
Only if glandular kallikrein were handled by the kidney in a uniquely different 
way from other proteins of similar molecular weight (i.e., no glomerular filtration 
or complete reabsorption in the tubule) would urinary kallikrein represent exclu-
sively kallikrein synthesized and secreted by the kidney. However, to our knowl-
edge no evidence is available suggesting a uniquely different handling of kallikrein 
by the kidney.1 Therefore, it seems very likely to us that urinary kallikrein 
does not originate exclusively from the kidney but also contains kallikrein of 
different origin. 
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referred in his discussion remark [see Discussion, this chapter] do not contradict our results. In 
stop-flow experiments similar results are to be expected for proteins, which are glomerularly filtrated 
and then partly reabsorbed in the proximal tubule, and for proteins, which are secreted into the 
urine in the distal tubule. In both cases the highest concentration of the protein would be found 
in the urine fractions corresponding to the distal tubule. 
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DISCUSSION 
D r . C a r r e t e r o : I think you have to differentiate between what happens in a normal 
situation and what happens with the infusion of kallikrein. In our stop-flow studies, 
we never found kallikrein in the proximal tubule, indicating that the kallikrein was 
not filtered. A kallikrein peak was found in the distal nephron, indicating that the kalli-
krein in the urine was coming from this part of the kidney. Of course, I would not 
say that this occurs also in the case of pancreatitis, where a considerable amount of 
kallikrein enters the circulation. When kallikrein is injected, it binds to inhibitors that 
have a high molecular weight and will not be filtered in the kidney. However, you 
assume that kallikrein is circulating freely even though you demonstrated that kallikrein 
is bound to the inhibitors and that it is inactive. Are you proposing a renal mechanism 
for cleaving kallikrein from the inhibitor and then filtering it? 
D r . F i n k : The slide with the gel filtration of rat serum and rat lymph showed two 
peaks of pig pancreatic kallikrein, the smaller peak was unbound kallikrein. This demon-
strates that injected kallikrein is partly bound to ai-antitrypsin or whatever the inhibitor 
is, but some of the kallikrein is still present in the free form. The complex formation, 
at least i n vitro, occurs relatively slowly. Therefore, if kallikrein is infused intravenously, 
part of it should be present in the free form during the infusion. 
D r . C a r r e t e r o : How do you explain then that, after intravenous injection of kallikrein, 
the depressor effect disappears almost immediately? What proportion of the urinary 
kallikrein do you feel comes from organs other than the kidney? 
D r . F i n k : Kallikrein, which circulates in the blood, may still be of renal origin. It 
may be secreted into the blood first and then filtered in the glomeruli, so it still may 
be kidney kallikrein. 
D r . C a r r e t e r o : Let me put it another way. What proportion of the kallikrein that 
you find in the urine was secreted directly into the lumen of the distal tubule, and 
what proportion was filtered through the glomeruli? 
D r . F i n k : We calculated that in these experiments, at least up to 50 fig of the human 
urinary kallikrein is filtered in the kidney, maybe even more, but at least 50 /mg. 
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D r . C a r r e t e r o : When the inhibitor takes 24 hr to bind kallikrein, how do you explain 
then that, after injection of kallikrein, the depressor effect does not last, but disappears 
immediately? 
D r . F i n k : If you inject relatively high doses of kallikrein, the lowering of blood pressure 
lasts for several hours; if you inject only small doses, as for measuring kallikrein concentra-
tions by the response of blood pressure, this response lasts only for a very short period. 
D r . H e i m b u r g e r : Concerning the interaction, respectively the unspecific binding of 
kallikrein by antithrombin III: it is well known that antithrombin III is rich in carbohy-
drates, and we found that antithrombin III combines with lectines of a defined carbohy-
drate composition. I presume that the nonspecific binding is due to an interaction of 
the carbohydrates of kallikrein and antithrombin III, and I think the carbohydrate com-
position might also be of importance for the distribution of kallikrein in various organs 
and in the body fluids. You should be able to check it by treatment of the inhibitor, 
kallikrein, or both with neuraminidase. 
D r . Vogt: In your immunodiffusion experiment, the three kallikrein preparations gave 
completely fusing precipitation lines with antiserum directed against one of them. Did 
you repeat the experiment with antisera raised against one of the other two kallikrein 
preparations? If so, was there again complete fusion or did spurring occur, indicating 
only partial immunochemical identity? 
D r . F i n k : Such experiments were done, there was again complete fusion. 
D r . F r i t z : Dr. Fink showed that, with the amount of kallikrein he injected, the kallikrein 
concentration in dog serum never rose above the normal level measured in pig serum. 
Nevertheless, he found kallikrein excreted in the urine. In the pig, this experimental 
approach was impossible because of the immunological identity of the exogenous and 
endogenous glandular kallikreins. He had to apply, therefore, higher kallikrein doses 
in the pig. I think, however, when a blood-kallikrein level within the physiological range— 
as it was the case in the dog experiments—leads to an excretion of kallikrein in the 
urine, this could also occur under normal conditions. 
D r . M i l l s : If I could come back to the point that Dr. Carretero was mentioning: If 
you inject enough kallikrein to have any measurable effect on blood pressure, you increase 
vascular permeability and this effect on vascular permeability far outlasts the length of 
time for which the blood pressure changes. With this increased vascular permeability, 
large proteins escape, even globulins, and I think it is quite likely that the glandular 
kallikrein might then be filtered in the glomerulus. 
D r . F i n k : The only control we did with the dog was the determination of protein in 
the urine. Since the urine was quite diluted, we found a lowering of protein concentration. 
We tried to determine amylase activity but, obviously, the dog does not have amylase 
in the urine. We plan to do control experiments with added proteins of lower molecular 
weight. However, I do not think that the renal excretion of kallikrein is an artifact. 
Just from the physiological point of view, the barrier for glomerular filtration is about 
70,000 dalton and one has to expect that kallikreins with a molecular weight of 30,000, 
40,000 can be filtered. 
D r . M i l l s : When you put in labeled kallikrein in such a small amount that the blood 
pressure does not change, then we find less than 8% comes out in the fraction which 
contains active kallikrein. 
D r . F i n k : I found up to 3%, so it was still a small amount, but enough to explain a 
large part of the urinary kallikrein. 
D r . Erdas: You have shown that only the pancreatic kallikrein has two chains, while 
the others have a single chain. Is that due to cleavage of the single peptide bound 
during extraction, or is it the native form of the pancreatic kallikrein? 
D r . F i n k : It is obviously an artifact caused during the isolation procedure. The pan-
creatic kallikrein which we use is isolated from autolyzed pancreas. Recently, Drs. Fiedler 
and Gebhardt isolated prekallikrein, which is not yet pure. The prekallikrein is obviously a 
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single chain and all of the activated prekallikrein is a single chain. The two-chain kallikrein 
obviously has lost a peptide of three-amino acids. This is the difference between the 
amino acid compositions of the pancreatic kallikrein and the submandibular and urinary 
kallikrein. 
D r . P h i l l i p s : I heard this morning that there are kinins in the brain. Does kallikrein 
pass through the blood-brain barrier, or is there an endogenous source in the brain? 
D r . F r i t z : The presence of kininogenases and kininases in brain tissue was described 
in earlier experiments by Werle, Frey, and Kraut. We know that various tissue cells 
contain kininogenases as well as kininases, e.g., mast cells, fibroblasts, etc. As far as I 
know these are not kallikreins in the strict sense as they are present in pancrease and 
submandibular gland. For example, cathepsin D, which is present in the brain, is also 
a potent kininogenase. It liberates leucokinins which are very similarly to normal kinins, 
from leucokininogen, probably also present in the brain. 
D r . C a r r e t e r o : Kininogenase activity in the arterial wall has recently been described 
by Dr. Nolly. Unfortunately, this kininogenase is only active at acid pH, indicating 
that it may be a cathepsin. 
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